What's Macquarie's price target for NIB shares?

Is the broker positive or negative on NIB's shares?

| More on:
Private health insurance diagram.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Ltd (ASX: NHF) share price has slipped slightly this morning. As of 11 am, shares are trading 0.81% lower at $7.35 a piece.

NIB's share price has jumped 33.1% since January. But thanks to a steep 17.8% plunge in late-August last year, the health insurer's share price is still down 2.26% for the year.

In a recent note to investors, Macquarie Group Ltd (ASX: MQG) revealed what it expects for NIB's share price over the next 12 months.

Macquarie's stance on NIB shares

The broker has confirmed its underperform rating on NIB shares and its target price of $5.60. 

That represents a potential downside of 23.8% for investors over the next 12 months.

"With multiple divisions experiencing operational and environmental headwinds, we retain our cautious outlook," Macquarie said in its note.

Macquarie expects more political and regulatory risk in FY 2026 as the Health Minister takes a second term and government focus on NDIS funding intensifies.

What to keep an eye on

Key catalysts to watch are the government review into phoenixing – where a company is deliberately liquidated to avoid paying debts before being restarted under another name, changes to the price approval process, changes to the student deed, and findings of the PALM (Pacific Australia Labour Mobility scheme) review.

Macquarie notes:

Residents – Payout Ratio: We expect further direction from the Department of Health on #1) phoenixing; #2) look-back mechanism for price approval, and #3) limits to "free periods", to be released over CY25 and impact CY26 results: "Why a claims payout ratio misses the mark" published 13 Jun '25. Worst case: this accounts for ~12.4% of Group UOP by FY27.

It adds that for international workers, even if NIB retains the PALM contract, it is unlikely to retain the high margins it enjoyed previously. At worst, this could account for 2.5% of the group's underlying operating profit or 4%-5% of the group's underlying operating profit with 50% stranded costs. It also said:

International – Students: NHF's costs are below the 12% commission cap so we foresee this change having limited impact. […] Worst case: this accounts for ~2.2% of Group UOP, before stranded costs and potential knock-on for residents.

For NDIS funding, the broker expects earnings declines in the coming 18-24 months as scheme reform remains elusive. In a worst-case scenario, this could account for 4.8% of the group's underlying operating profit. 

Macquarie notes that a new division head has been appointed to NIB New Zealand. This could pose a downside earnings risk as high as 6.6% on the group's underlying operating profit.

Earnings changes: FY25E: +1.8%; FY26E: -3.6%; and -1% to -5% for FY27 to FY29 reflecting above mentioned divisional challenges and MTMs.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Healthcare Shares

Top broker says this ASX small-cap healthcare stock could be set to double

This company is making significant clinical and commercial progress .

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 quality ASX healthcare shares worth buying now

Brokers think the tide is turning for these battling medical heavyweights.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring

The early-stage results have been described as outstanding.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why are 4DMedical shares in a trading halt today?

The company is looking to raise fresh capital.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech's shares are up strongly on good news out of the US

The addressable market for this newly approved software is huge.

Read more »